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Abstract: Before the age of 75 years, approximately 10% of women will be diagnosed with breast cancer, one of the most 
common malignancies and a leading cause of death among women. The objective of this study was to determine if 
expression of the nuclear receptor coactivators 1 and 3 (NCoA1 and NCoA3) varied in breast cancer grades. RNA was 
extracted from 25 breast tumours and transcribed into cDNA which underwent semi-quantitative polymerase chain 
reaction, normalised using 18S. Analysis indicated that an expression change for NCoA1 in cancer grades and estrogen 
receptor alpha negative tissue (P= 0.028 and 0.001 respectively). NCoA1 expression increased in grade 3 and estrogen 
receptor alpha negative tumours, compared to controls. NCoA3 showed a similar, but not significant, trend in grade and a 
non-significant decrease in estrogen receptor alpha negative tissues. Expression of NCoA1 in late stage and estrogen 
receptor alpha negative breast tumours may have implications to breast cancer treatment, particularly in the area of 
manipulation of hormone signalling systems in advanced tumours. 
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INTRODUCTION 
 Breast cancer is one of the most common forms of 
cancer, causing much morbidity and mortality worldwide. 
Current health estimates indicate that around 10% of women 
in industrialised countries like the USA and Australia will 
develop breast cancer at some time in their lives [1, 2]. The 
growth of breast tumours and benign breast tissue is driven 
by several cellular signalling methods, of which the most 
important is considered to be estrogen [3]. The effects of 
estrogen are primarily modulated through the estrogen 
receptors alpha and beta (ESR and ESR), members of the 
nuclear receptor superfamily, which have genomic and non-
genomic mechanisms [3, 4]. In order to activate specific 
functions, estrogen binds to its receptors, which dimerise and 
recruit additional cofactors before moving on to affect 
metabolism or gene expression [4]. Among the estrogen 
cofactors are the nuclear receptor co-activator (NCoA) family 
of co-enzymes. This family is involved in the function of 
most known hormone receptors [5]. Members of the NCoA 
family have additional names according to their functions or 
protein associations, notably NCoA3, with the alternative 
name AIB1, or Amplified in Breast Cancer. As this implies, 
the over-expression of NCoA3 and other NCoA family 
members has been found to increase the transactivation 
function of several nuclear receptors, and evidence suggests 
that they are required for the function of nuclear receptors 
[6]. The NCoA proteins interact with ligand binding domains  
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of nuclear receptors, binding both receptors in a dimer 
through LXXLL amino acid motifs present on both the 
NCoA and nuclear receptor (NR) proteins [6, 7]. Once 
bound to the activated nuclear receptor, the NCoA protein is 
able to recruit the CBP/p300 and p/CAF protein complexes, 
both of which have an acetyltransferase activity, which 
results in the acetylation of histone proteins, which is 
required for the de-repression of the genes controlled by the 
nuclear receptors [6, 8]. Members of the NCoA family are 
also known to have a weak histone acetyltransferase activity, 
and there is some evidence that NCoA family members may 
cooperate in other signalling pathways [9]. Binding to the 
other cofactors required for NR function also appears to be 
mediated by the LXXLL motifs, reinforced by crystal 
structure analysis and the conservation of these motifs in the 
genes, indicating that they perform some important function 
in the overall receptor/coactivator complex [6, 8, 10]. 
 It is currently poorly understood if NCoA proteins are 
specific for certain nuclear receptors, as well as whether or 
not they control additional cofactor recruitment, and thus the 
final function of the NR complex. However, some evidence 
from peroxisome proliferator-activated receptor gamma 
binding assays indicates that the specific NCoA bound to a 
NR complex does affect the binding of other cofactors [11]. 
The specificity of the NCoA proteins may be mediated via 
amino acids bordering LXXLL motifs that bind NRs [6, 7, 
11]. Other studies support this, indicating that NCoA1 
activity is restricted to the nuclear receptors that accept 
hormone signals [8]. However, studies of NCoA ablation 
have shown that loss of NCoA1 does not remove the normal 
responses to hormonal signals. Cells losing NCoA1 often 
respond by up-regulation of NCoA2, indicating that the 
NCoA family may not be entirely locked into receptor 
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specificity, which is perhaps mediated by NCoA isoform 
splicing [6, 8]. More recent studies have indicated that 
NCoA recruitment to receptor complexes may be mediated 
by phosphorylation and other post translational 
modifications of the NCoA proteins, functions modulated by 
specific kinases [12]. While other research has investigated 
protein expression of the NCoA genes in breast cancer, this 
study aimed to determine how the mRNA expression levels 
of the nuclear receptor coactivators 1 and 3 (NCoA1 and 
NCoA3) varied in different breast cancer grades as a 
potential reflection of underlying transcriptional pressures. 
MATERIALS AND METHODOLOGY 
Tissue Population 
 The tissue population for this study was comprised of 25 
archived breast tissue sections embedded in paraffin and 
fixed with 10% buffered formalin on slides. 10 micron thick 
sections were supplied with haemotoxylin and eosin (H&E) 
stained slides as a reference for tumour location. All tumour 
samples were diagnosed as infiltrating ductal carcinoma. 
There were 6 samples from tumour grade 1, 7 samples each 
from grades 2 and 3 and 5 samples of benign breast tissue 
taken from unaffected patients as a control population. The 
average age of the individuals from whom the biopsies were 
obtained were 56.88 years, 59.18 years, 60.45 years and 
55.93 years for the control and grades 1, 2 and 3, 
respectively. The archival breast tissue samples were 
obtained through collaboration with Gold Coast Hospital 
Pathology, with relevant ethical approvals (Approval 
numbers HSC/04/03/HREC and 9702 for Griffith University 
and Gold Coast Hospital, respectively). For consistency, 
cancer grading for each sample was confirmed by a single 
pathologist from the Gold Coast Hospital’s Pathology 
Department (SRW). There was a variety of pathological data 
available for the population, including immunohistochemical 
staining to detect ESR proteins. ESRa status was 
determined by standard clinical criteria for treatment. A 
summary of the population’s ESR status can be found in 
Table 1. 
Table 1. Population ESR  Immunohistochemical Staining 
Status 
 
Tumour Grade ESR  Positive ESR  Negative Total 
Control 5 0 5 
Grade 1 6 0 6 
Grade 2 5 2 7 
Grade 3 2 5 7 
 
RNA Extraction 
 RNA extraction and cDNA synthesis was performed as 
outlined in previous publications by Smith et al. [13]. 
Tumour tissue was first separated from the surrounding 
tissue by microdissection under an Olympus BX60 
microscope (Olympus Optical Co., Tokyo, Japan), using 
supplied H&E slides as a guide to tumour location. All non-
malignant tissue was removed as a single unit for separate 
analysis. Paraffin was removed with xylene, the tissue 
homogenised by passage through an 18G needle and then 
subjected to 1 hour of treatment with TRIzol reagent. RNA 
was separated from DNA and protein through the use of 
chloroform and centrifuging. Extracted RNA was treated 
with Rnasin and Dnase I. Finally, RNA was further purified 
using a Qiagen Rneasy Mini Kit. cDNA was generated in a 
25mL reaction using 2ng of total RNA, Superscript III from 
Invitrogen (0.2μL/reaction), random hexamers (9μg/reaction), 
5mM dNTPs (0.5μL/reaction) and 1x Superscript buffer 
(Invitrogen). 
Expression Assay 
 cDNA was made using the method outlined above 
underwent PCR with fluorescently labelled primers to 
amplify cDNA corresponding to mRNA for NCoA1 and 3. 
Individual samples underwent semi-quantitative PCR in 
triplicate for each gene before results were pooled and 
analysed. Primers for the NCoA1 and NCoA3 genes in this 
experiment were intron spanning, however, because the 
introns were kilobases in length and unlikely to amplify in a 
PCR optimised for small fragments, intronic primers 
previously used for the glucocorticoid receptor were 
multiplexed into the NCoA PCRs to detect genomic DNA 
present. No genomic DNA contamination was observed in 
any sample. NCoA genes were multiplexed with primers for 
ribosomal 18S RNA, as a ubiquitous control. Amplicons for 
NCoA genes were approximately 100 base pairs long, 
allowing cDNA derived from partially degraded RNA to be 
identified. Amplicons produced by contaminating genomic 
DNA present were 150bp in length. 18S amplicons were 
approximately 70bp long. Primers appear in Table 2. 
Table 2. Primer Compositions 
 
Primer Name Sequence (5’-3’) 
NCoA1-F1* CATTCCCCGGGAAGCTAC 
NCoA1-R1 TTCACACCTGGGAGACTTCTT 
NCoA3-F1* TGGTTAGCCAGTTGCTGATGT 
NCoA3-R1 GCAATTTGCGTTTTCGTGA 
Glucocorticoid receptor-F* GAGTACCTCTGGAGGACAGA 
Glucocorticoid receptor-R ATGTCCATTCTTAAGAAACAGGA 
18S-A# CTTAGAGGGACAAGTCGCG 
18S-B GGACATCTAAGGGCATCACA 
*= Primer labelled with TET at 5’ # = Primer labelled with HEX at 5’. 
 
 PCR for both genes was carried out for 25 cycles in a 
mixture of 5.5μl Master Amp Premix C or L, for NCoA1 and 
3, respectively (Epicentre, Madison, USA), 2μl of each of 
the two primers, 1μl of the two reference gene primers, 2μl 
of the cDNA sample (18-20ng/μl ), 0.2μl Taq polymerase 
and 0.3μl of water. Prior to initiating PCR, the reaction 
mixture was heated at 95°C for five minutes to dissociate 
any secondary structures. The parameters for one cycle of 
the PCR reaction were denaturation at 95°C for one minute, 
annealing at 57°C for one minute and thirty seconds and 
extension at 72°C for one minute. Gene expression was 
quantified by expressing data as a ratio of NCoA to 18S, 
using an ABI 310 Genetic Analyzer, utilizing peak height as 
the measure of expression. 
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Statistical Analysis 
 Averaged expression data for individual samples 
obtained for the NCoA1 and 3 genes was normalised using 
the expression data obtained for the 18S gene. The 
normalised data were then analysed using one-way analysis 
of variance (ANOVA) to determine whether there was a 
significant difference between tumour grades and 
surrounding tissues or between tissues based on ESR 
status. For ESR status, expression values for the 
surrounding tissue for each tumour was included in the same 
category as the primary tumour, as a measure of the broad, 
tissue specific effect of tumour ESR status on NCoA 
transcription. Control tissue was included in this analysis and 
forms part of the ESR category. Appropriate post hoc tests 
were subsequently performed to elucidate any differences 
found. P < 0.05 was considered statistically significant. The 
software package SPSS version 10.1 was employed for all 
statistical analyses (SPSS Inc., Chicago, IL, USA). 
RESULTS 
 The expression levels for the NCoA1 and NCoA3 genes 
were determined in all samples, both tumour and stroma. 
Comparisons were then made using the grade of tumour and 
the tissue’s ESR protein status as grouping variables. 
Expression ratios (NCoA/18S) in different grades of tissue 
can be seen in for NCoA1 in Fig. (1), while the NCoA3 
results can be seen in Fig. (2). The expression ratios for the 
ESR status categories can be seen for both NCoAs in Fig. 
(3). 
 Despite the appearance of some changes in NCoA 
expression in different tissue categories, after ANOVA 
analysis, the differences was significant only for NCoA1. 
The p value for ANOVAs conducted on NCoA1 were 0.028 
for cancer grade and 0.001 for ESR status. By contrast, the 
p values for NCoA3 were 0.322 for the cancer grade analysis 
and 0.365 for the ESR protein analysis. Post-hoc tests on 
NCoA1 data indicated that the expression of NCoA1 was 
elevated in grade 3 tumours, but only in comparison to grade 
1 tumours. For ESR protein status, the expression of 
NCoA1 significantly increased in ESR negative tissues, 
both in tumour and stroma derived from tumours, compared 
to ESR positive tissues. Expression data for NCoA1 and 
NCoA3 was normally distributed, with p values from the 
homogeneity of variances test being 0.089 and 0.107, 
respectively. 
DISCUSSION 
 The NCoA family are transcription factors that bind to 
signalling proteins and recruit further proteins to the 
signalling complex, modulating the effects of incoming 
messengers, including steroid hormones and others, such as 
transforming growth factor  [6, 7, 14]. As such, they have a 
role to play in multiple processes, including cellular growth, 
function and differentiation, making their regulation 
important in the development and progression of cancer [6, 
7, 15]. The results of these studies showed that the mRNA 
expression of NCoA1 is significantly affected by both cancer 
grade and ESR protein status in the test population, while  
NCoA3 mRNA expression remains unchanged in all classes 
of tissue. 
 For NCoA3, the data indicated that there was no 
significant association between the mRNA expression of this 
gene and either cancer grade, or ESR protein status. In part, 
this was an unexpected result, since NCoA3 has been found 
to have increased expression in breast cancer in cell lines and 
biopsies [15, 16]. This trend is not universal, however, and 
other studies have found that the expression of NCoA3 
remains unchanged in some cell lines [15, 17]. It is worth 
noting that the general level of expression for NCoA3 in this 
study was higher than NCoA1 and expression of NCoA3 in 
grade 3 tumours is higher than in control tissues, though this 
 
Fig. (1). Expression of NCoA1 in tissue derived from different tumour grades and surrounding stroma. 
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was not significant. NCoA3 may not be over-expressed in the 
tumours because the particular alterations to growth 
induction pathways that these tumours are using do not 
require NCoA3. It is also possible that the cells are not 
experiencing a significant increase in NCoA3 expression 
because the NCoA requirement of the cells is being fulfilled 
by the increased NCoA1 expression or other cofactors. It is 
also possible that post transcriptional modification of the 
NCoA3 mRNA modulates its function, removing the 
necessity to increase expression to achieve a specific 
function. Finally, there is the possibility that the relatively 
low number of tumours available, or the semi-quantitative 
nature of this PCR do not allow this study sufficient 
resolution to identify which tumours overexpress NCoA3, 
and why. 
 The results for NCoA1 indicated that the expression of 
that gene is increased in late stage breast cancer. This result 
 
Fig. (2). Expression of NCoA3 in tissue derived from different tumour grades and surrounding stroma. 
 
Fig. (3). Expression of NCoA1 and NCoA3 in Tissue Derived From Different Tumour Grades and Surrounding Stroma, Compared by ESR 
status. 
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was not entirely unexpected, as the mRNA expression of 
NCoA family members, have been found to be up-regulated 
in many cancers, including breast tumours and cell lines [15-
17]. Such up-regulation may increase the activity of a large 
range of target genes and can affect cells in many ways. 
Proteins that promote and repress cellular division are 
assisted in their function by NCoA1, which is often 
associated with the steroid hormones. This means that an 
increase in expression may not have specific effects on the 
tumour cells, contributing to cellular behaviour in concert 
with other co-activators and the signalling milieu the cells 
are in. The results for NCoA1 also indicated that the 
expression was increased in grade 3 tumours in comparison 
to grade 1 tumours only, which are not significantly different 
to any other class of tumour, nor are they different to control 
or stromal tissue. Hence, although the expression of NCoA1 
was high in grade 3 tumours, it was not significantly higher 
than the expression of NCoA1 in control tissue. This is 
perhaps not a reflection of a difference between grade 1 
tumours and grade 3, but rather simple variation between the 
tumours, as the error bars in Fig. (1) demonstrate 
considerable differences within the grades. This, however, is 
consistent with results from other studies, which indicate that 
over-expression of the NCoA family is not universal for all 
cell lines or tumours, though it does occur [15-17]. More 
likely to be the result of a specific effect was the outcome of 
the ESR protein analysis, which indicated that the mRNA 
expression of NCoA1 was higher in tissues that are 
ESR negative. With a p value of 0.001, this association was 
stronger than that of the cancer grade (p= 0.028) and has 
lower variation in the groups, reinforcing the correlation 
between the loss of the ESR protein and an increase in 
NCoA1 expression. It is also possible, however, that the 
difference observed was because nearly all ESR negative 
tissues in this study were grade 3 tumours. 
 These results are more interesting in the light of a recent 
study by Green et al, who subjected a large series of breast 
tumours to immunohistochemical detection of a large 
number of proteins, including NCoA1 and 3. Their study 
indicated that the reverse of this relationship was taking 
place at the protein level, that NCoA1 expression was higher 
in lower grade, less malignant and ESR negative cancers 
[18]. In addition, they linked higher NCoA1 expression with 
less aggressive cancers and longer disease free survival. At 
first glance, it would seem counterintuitive that there should 
be so great a discordance between the results for mRNA and 
protein levels. However, earlier work in the population in 
this study has shown a very similar disconnect, as ESR 
mRNA remains detectable and nearly identical to control 
tumour tissue in all samples, including those negative for the 
ESR protein [13]. Likewise, earlier work in this population 
has indicated that the mRNA for numerous nuclear receptors 
inhibiting growth, such as the androgen, glucocorticoid and 
progesterone receptors increases in later stage breast cancers, 
though no direct protein comparisons are yet available [13, 
19]. Experience in breast cancer tissues would indicate that 
the protein expression of these receptors reduces in later 
stage cancers [20]. 
 The differences between the results of protein based 
studies, such as those of Green et al. and mRNA studies such 
as this one may reflect fundamental shifts in the way that 
hormone receptor and co-factor genes like the NCoAs are 
regulated as breast cancer grows and progresses. Advanced 
and more aggressive tumours may be expressing the mRNA 
for growth inhibiting proteins as part of a pre-existing and 
still functional growth feedback pathway, but some other 
mechanism is preventing the protein from being produced. 
Potential mechanisms for this include post-translational 
modification of the final protein or production of alternative 
protein isoforms, perhaps with alternative functions. Both of 
these mechanisms have the potential to confuse the 
immunohistochemical methods used by Green et al. due to 
epitope shifts, while different mRNA isoforms may also lead 
to misleading results from PCR based approaches, such as 
this study. It is also possible that miRNA expression is 
ablating mRNA species responsible for production of 
NCoA1 and related genes that produce mRNA, but for which 
proteins are lost in late stage breast cancers. 
CONCLUSION 
 Taken together with previous research from this tissue 
population and the results of protein based studies, these 
results indicate that growth braking mechanisms in cancer 
cells may still be partially functional, driving tumours to 
produce anti-growth mRNA, but that some as yet unknown 
mechanism, perhaps miRNA or protein modifications, 
prevents the production of significant quantities of complete 
protein. If there is such a translation changing mechanism at 
play in breast cancer cells and it could be blocked, normal 
hormone receptor systems and response to hormonally based 
treatment may be restored. Understanding which cofactors 
are favoured by cancers in particular pathological states and 
how they affect signalling may aid in designing targeted 
hormone therapies after responsiveness is restored. This 
complex state of affairs reinforces the need to examine the 
biology of cancer cells at all available levels, as what may 
seem relatively simple associations for individual markers 
with clinical parameters may be part of larger shifts in 
complex cellular biology that can be detected when all 
aspects are considered. Further research should confirm the 
expression levels of these proteins directly and attempt to 
identify if alternative mRNA isoform proportions and 
miRNA expression using a more directly quantitative 
methodology, as well as modified proteins, are associated 
with clinical parameters, as these may give clues to the 
larger story unfolding within breast cancer cells. 
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